Cygnus GlucoWatch Distributor Asks For Proof Of Fiscal Stability By Oct. 16
This article was originally published in The Gray Sheet
Executive Summary
Cygnus alleges it will suffer $450 mil. in damages and lose $1 bil. in potential revenue over the next 12 years if Sankyo Pharma ceases marketing and distribution of its GlucoWatch non-invasive glucose monitor